Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab plus TACE for Liver Metastatic Melanoma
NCT05647954Phase 3Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pucotenlimab in melanoma (3 arms), sponsored by Taizhou Hanzhong Pharmaceuticals. Primary endpoints: Progression-free Survival at 2 years and Overall Survival at 2 years. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05647954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647954.